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Sopungyangjae-Tang (SYT) is a traditional Korean decoction used for the treatment of
dermatitis. The aim of this study was to confirm whether or not SYT has a preventive effect on
the development of atopic dermatitis in dinitrochlorobenzene-applied Nc/Nga mice. SYT was
administered orally to Nc/Nga mice, which led to the remarkable suppression of the
development of dermatitis, as determined by a histological examination and the serum IgE
levels. Moreover, SYT inhibited the production of thymus- and activation-regulated chemokine
(TARC) and its mRNA expression in a keratinocyte cell line, HaCaT, which had been
stimulated with tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g). Activation of the
nuclear factor-kB (NF-kB) or activator protein-1 (AP-1) is one of the key steps in the signaling
pathways mediating induction of TARC. In this study, SYT selectively suppressed NF-kB
activation, which may be essential for TARC expression in TNF-a/IFN-g treated keratinocytes.
The inhibitory effect of SYT on NF-kB activation and TARC production might be associated
with the anti-dermatitic effects of SYT.
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Introduction
Atopic dermatitis is a clinical syndrome that is
characterized by pruritic skin lesions that are distin-
guished by infiltrating lymphocytes, macrophage and
granulated mast cells (1,2). Atopic dermatitis is a
common disease with an increasing incidence in indus-
trialized countries. Although topical steroid therapy is
used to manage this disease (3), many patients suffer
from the serious side effects of steroid ointments. Hence,
a great deal of effort has been directed toward identifying
safer compounds or herbal remedies that can inhibit the
development of atopic dermatitis.
Some traditional Korean herbal prescriptions have been
clinically applied as curative agents against incurable
chronic diseases. Sopungyangjae-Tang (SYT) is widely
used in Korea for the treatment of dermatitis. SYT is a
decoction consisting of 15 medicinal plants, Angelicae
Gigantis Radix, Moutan Cortex, Rehmanniae Radix,
Glycyrrhizae Radix, Linocerae Flos, Ledebouriellae
Radix, Spirodelae Herba, Forsythiae Fructus, Paeoniae
Radix Rubra, Cnidii Rhizoma, Schizonepetae Herba,
Bombyx Batryticatus, Menthae Herba, Bubali Cornu and
Scutellariae Radix.
One of the endogenous ligands for CC chemokine
receptor 4 (CCR4) is the thymus- and activation-
regulated chemokine (TARC/CCL17), which preferen-
tially attracts Th2 cells and regulatory T cells via CCR4
(4). TARC is synthesized by dermal dendritic cells that
have differentiated from monocytes with GM-CSF and
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properly cited.IL-4 (5). TARC produced from basal keratinocytes play
a significant role in recruiting Th2-type lymphocytes to
dermatitic skin lesions and the subsequent deterioration
of dermatitis (6,7).
It has been reported that Nc/Nga mice develop
dermatitis with depilation and hemorrhage when housed
in conventional conditions but not in specific pathogen-
free conditions (8). This study investigated the pro-
tective effect of SYT on development of dermatitis in
Nc/Nga mice that had been topically applied with
1-chloro-2,4-dinitrobenzene (DNCB). The effect of SYT
on TARC production in a keratinocyte cell line, HaCaT,
was also examined to elucidate a possible mechanistic
basis for the anti-dermatitic effects of SYT.
Methods
Mice
The Institutional Animal Care and Utilization Committee
of Chosun University approved all animal procedures.
Male Nc/Nga and ICR mice (weighing 25g) were
purchased from Joong-Ang Experimental Animals Co.
(Seoul, Korea), placed in cages at a temperature between
20 and 23 C with a 12h light and dark cycle and a
relative humidity of 50%. Animals were given commer-
cial mouse chow (Purina, Korea) and water ad libitum.
Controlled dermatitis was induced by topically applying
0.1% DNCB dissolved in acetone/olive oil (1:3), to the
hair-removed back of mice 3 times per week (Monday,
Wednesday and Friday) for 10 weeks. Mice were
then housed for 3 days without any further treatment.
In the case of the SYT-treated group, SYT was orally
administered at a dose of 20, 40 or 60mg/mouse (6 times
per week for 12 weeks) in their drinking water. Control
animals received the vehicle. Mice were sacrificed on the
day of the experiment (on 73 days after first applying the
DNCB) and blood was collected from the vena cava. Skin
tissues from the backs of mice were excised and subjected
to histological examination.
Preparation of Sopungyangjae-Tang
All medicinal plants were purchased from a herbal market
(Daewon, Daegu, Korea) and was authenticated by
Professor Sang Chan Kim, Daegu Haany University.
Herbarium voucher specimens of SYT were prepared
and deposited in the herbarium of the Graduate
School of Oriental Medicine, Daegu Hanny University.
The SYT used in this study was composed of 12g
Angelicae Gigantis Radix, 12g Moutan Cortex, 12g
Rehmanniae Radix, 4g Glycyrrhizae Radix, 4g Linocerae
Flos, 4g Ledebouriellae Radix, 4g Spirodelae Herba,
4g Forsythiae Fructus, 4g Paeoniae Radix Rubra, 4g
Cnidii Rhizoma, 4g Schizonepetae Herba, 4g Bombyx
Batryticatus, 2g Menthae Herba, 2g Bubali Cornu and
2g Scutellariae Radix. A water extract of SYT was
prepared by boiling 1560g SYT in 4l of distilled water
at 100 C for 3h. The extract was centrifuged 3000g for
3min and the resulting supernatant was lyophilized to
produce a powder (232.6g), which was stored at 4 C.
Other Materials
Anti-phospho inhibitor-kBa(I-kBa) antibody was
supplied from Cell Signaling Technology (Beverly, MA,
USA). The recombinant tumor necrosis factor-a (TNF-a)
and tumor necrosis factor interferon-g (IFN-g) were
obtained from Peprotech Inc. (Rocky Hill, NJ, USA).
The human TARC and mouse IgE enzyme linked-
immunosorbent assay kits were purchased from R&D
Systems (Minneapolis, MN, USA) and Shibayagi Co.
(Gunma, Japan), respectively. 1-chloro-2,4-dinitroben-
zene (DNCB) was obtained from Aldrich (Milwaukee,
WI, USA). Most of the reagents used for molecular
studies were purchased from Sigma (St. Louis, MO,
USA).
Cell Culture
HaCaT cells, a human keratinocyte cell line, were
cultured in Dulbecco’s modified Eagle’s media
(DMEM) supplemented with 10% fetal calf serum
(FCS), 100mgml
 1 penicillin and 100mgml
 1 streptomy-
cin, in 5% CO2 at 37 C. Production of TARC was
stimulated by incubating HaCaT cells with 20ngml
 1
TNF-a and 20ngml
 1 IFN-g in. The SYT extract was
dissolved in sterile phosphate-buffered saline and added
to the incubation medium 10min before adding TNF-a/
IFN-g.
Enzyme Linked Immunosorbent Assay (ELISA)
Both the serum levels of IgE in the Nc/Nga mice and the
supernatant levels of TARC in HaCaT cells were
measured according to manufacturer’s instructions.
Absorbance was measured at a wavelength of 450nm,
and the concentration was calculated from a standard
curve using serially diluted IgE or recombinant TARC.
Histopathologic Examination
Skin tissues were isolated from each mouse and fixed in
10% formalin in 50mM of a phosphate buffer (pH 7.0)
for 24h at 4 C. Skin tissues were subsequently embedded
in paraffin, sectioned (4mm), stained with hematoxylin
and eosin, and examined by optical microscopy
(Olympus, Tokyo, Japan). A certified pathologist ana-
lyzed and scored the samples in a blinded manner. A
minimum of 2 sections per experimental animal were
examined for the presence and degree of incrustation,
thickening of the epidermis, epidermal necrosis, bleeding,
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Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated using the guanidium-isothiocya-
nate procedure, as described elsewhere (9). Total RNA
(1.0mg) obtained from cells was reverse-transcribed using
an oligo(dT) 20mer as a primer and Moloney-murine
leukemia virus reverse transcriptase (Bioneer, Eumsung,
Korea) to produce the cDNAs. PCR was performed
using the selective primers for the human TARC (sense
primer: 50-ACTGCTCCAGGGATGCCATCGTTTTT-30,
antisense primer: 50-ACAAGGGGATGGGATCTCCCT
CACTG-30) (270 bp) and the S16 ribosomal protein
(S16r) genes (sense: 50-TCCAAGGGTCCGCTGCAG
TC-30, antisense: 50-CGTTCACCTTGATGAGCCCAT
T-30) (152 bp). PCR was carried out for 35 cycles using
the following conditions: denaturation at 98 C for 10sec,
annealing at 60 C for 0.5min and elongation at 72 C for
1min. The band intensities of the amplified DNAs were
compared after visualization on a UV transilluminator.
Transient Transfection and nuclear Factor-kB (NF-kB)
and activator protein-1 (AP-1) Reporter Gene Assay
Cells were plated on a 12-well dish and transfected the
following day. Promoter activity was determined using a
dual-luciferase reporter assay system (Promega, Madison,
WI, USA). Briefly, cells were transiently transfected with
1mg of pNF-kB-Luciferase or pAP-1-Luciferase plasmid
and 20ng of the pRL-SV plasmid (Renilla luciferase
expression for normalization) (Promega, Madison, WI,
USA) using the Genejuice reagent (Novagen, Madison,
WI, USA), and then exposed to TNF-a (20ngml
 1)/
IFN-g (20ngml
 1) for 18h. The firefly and Renilla
luciferase activities in cell lysates were measured using a
luminometer (Turner Designs; TD-20, CA, USA).
Relative luciferase activity was calculated by normalizing
the NF-kB or AP-1 promoter-driven firefly luciferase
activity to that of Renilla luciferase.
Statistics
Differences between treatment groups were examined
using a paired Student’s t-test. The criterion for statistical
significance was set at either P50.05 or P50.01.
Results
SYT inhibits Dermatitis Progression in Nc/Nga Mice
Topically Applied with DNCB
Skin of the ICR or Nc/Nga mice bred under
conventional conditions for 10 weeks was first
investigated. Skin of ICR mice housed in conventional
conditions showed no physical signs of dermatitis
(Fig. 1A) or histological evidence of inflammatory
cell infiltration (Fig. 1A). Whereas, skin of Nc/Nga
mice bred in conventional conditions showed mild
thickening and incrustation on the back (Fig. 1B) as
well as histologically mild thickening of the epidermis
and a mild infiltration of inflammatory cells in the upper
dermis (Fig. 1B). In order to induce stronger and more
controlled dermatitis, 250ml of 0.1% DNCB was
topically applied to the back of the mice for 10 weeks
(3 times a week). The DNCB applied Nc/Nga mice
showed progressive diffuse erythematous changes, scal-
ing, lichenified areas, oozing and crusting on the back
(Fig. 1C) as well as histological findings of hyperker-
atosis, parakeratosis, acanthosis with varying degrees of
spongiosis, exocytosis of mononuclear cells in the
epidermis and infiltration of inflammatory cells into the
upper dermis (Fig. 1C). These results confirm that the
chronic application of DNCB can accelerate development
dermatitis of Nc/Nga mice.
The protective effects of SYT against DNCB-induced
dermatitis in Nc/Nga mice were examined. SYT (20, 40
and 60mg per mice) decreased the intensity of dermatitis
in the DNCB-applied Nc/Nga mice. The extent of
incrustation was particularly reduced by the administra-
tion of SYT [Fig. 1D (SYT 20mg per mice) and 1E (SYT
40mg per mice)]. Moreover, histological studies revealed
that thickening of the epidermis and infiltration of
inflammatory cells were significantly lower in the SYT-
treated groups [Fig. 1D (SYT 20mg per mice) and 1E
(SYT 40mg per mice)]. Multiple analyses of the histology
samples confirmed that SYT significantly reduced the
indices of dermatitis compared with that by DNCB alone
i.e. epidermal necrosis score: 2.8 (DNCB alone) versus
0.4 (SYT 20mg per mouse) or 0 (SYT 40mg per mouse)
(Table 1).
SYT Inhibits Serum IgE Increase in Nc/Nga Mice
Topically Applied with DNCB
IgE serum levels increased gradually with increasing age
of Nc/Nga mice, which is one of the indices for the
development of dermatitis (8,10,11). The application of
DNCB significantly enhanced the serum IgE levels
compared with the vehicle-treated group (Fig. 2). The
increased serum IgE levels were lower in the SYT-treated
groups. In the mice treated with 20 and 40mg SYT, the
serum level of IgE was 34 and 18% of that in the DNCB-
applied mice, respectively (Fig. 2). However, the serum
level of IgE in the 60mg per mouse SYT-treated group
was  50% of that in the DNCB-applied mice, but it was
not significantly different, which might be due to data
variances. Overall, these results suggest that the oral
administration of SYT prevents the development of
dermatitis in Nc/Nga mice.
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TARC is a type of secreted chemokine that attracts Th2
lymphocytes expressing CCR4 and is believed to be
involved in the development of Th2-mediated inflamma-
tion such as atopic dermatitis (4,12). Previous studies
have shown that TARC as well as the macrophage-
derived chemokine (MDC) actively participate in the
pathogenesis of atopic dermatitis in Nc/Nga mice (6). It
was reported that TNF-a and IFN-g synergistically
induce TARC production in primary human keratino-
cytes and HaCaT cells, which might play a role in the
development of atopic dermatitis (6). Because SYT
efficiently suppressed the development of dermatitis in
the DNCB-applied Nc/Nga mice, it was hypothesized
that SYT could affect the production of TARC in
HaCaT cells by TNF-a/IFN-g.
An ELISA assay using a human TARC specific antibody
showed that the level of TARC production was increased
3.2 fold by incubating cells with TNF-a (20ngml
 1)/IFN-g
(20ngml
 1) for 24h. however, this effect was not observed
with TNF-a or IFN-g alone (Fig. 3A, insert). Induction of
TARC production was inhibited significantly by a SYT
pretreatment (300 or 1000mgml
 1) in a concentration-
dependent manner (Fig. 3A). Expression levels of TARC
mRNA in HaCaT cells exposed to TNF-a (20ngml
 1)/
IFN-g (20ngml
 1) for 3h were measured in order to
determine if SYT inhibits the transcription of the TARC
gene. Expression of TARC mRNA was increased markedly
Figure 1. Representative photographs (Left panel) and hematoxylin/eosin staining (Right panel,  100) of skin sections from ICR (A)(n¼3) and
Nc/Nga mice treated with vehicle (B)(n¼3), DNCB (0.1%, 3 times per week for 10 weeks) (C)(n¼6), DNCB þ SYT (20mg per mouse, 6 times per
week for 10 weeks) (D)(n¼6) and DNCBþSYT (40mg per mouse, 6 times per week for 10 weeks) (E)(n¼6).
Table 1. Effect of SYT on pathological parameters of dermatitis in Nc/Nga mice
Group Parameter
IncruR E/Thick E/Nec Inf/Epi
ICR (Vehicle) (n¼3) 0.02 0.03 0.10 0.003 0 0
Nc/Nga (Vehicle) (n¼3) 0.03 0.05 0.10 0.02 0 0
Nc/Nga (DNCB) (n¼6) 0.31 0.19 0.17 0.03 2.5 1.2 2.8 0.4
Nc/Nga (DNCB)þSYT 20mg per mouse (n¼6) 0.02 0.03 0.10 0.01 1.3 1.5 0.8 1.2
Nc/Nga (DNCB)þSYT 40mg per mouse (n¼6) 0 0.10 0.01 0.5 1.2 0
Nc/Nga (DNCB)þSYT 60mg per mouse (n¼3) 0.02 0.03 0.10 0.002 0 0
IncruR, incrustation ratio¼Total length of incrusted areas/Total length of each sample; E/Thick, epidermal thickness; E/Nec, epidermal necrosis (no
necrosis, 0; mild, 1; moderate, 2; severe, 3); Inf/Epi, inflammatory cells infiltration in the epidermis (no infiltration, 0; mild, 1; moderate, 2; severe, 3);
Data represent the means SEM of 3–6 different samples.
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reversed by the presence of 300 or 1000mgml
 1 SYT. In
contrast, whereas the expression of the S16rRNA protein
mRNA was unchanged (Fig. 3B). Hence, SYT might be
associated with the TARC transcription pathway.
SYT Selectively Inhibits NF-kB Activation in HaCaT
Cells Stimulated with TNF-a/IFN-g
NF-kB and AP-1 are activated in cells stimulated with
TNF-a and IFN-g, which is involved in the transcrip-
tional activation of responsive genes (13–15). The
promoter region of the TARC gene contains NF-kB
and AP-1 binding sites (16), and recent studies revealed
that the transcriptional regulation is also related to the
NF-kB or AP-1 activity (16–18). Therefore, reporter gene
analyses using luciferase reporter plasmids containing the
NF-kB or AP-1 binding sequences were carried out in
order to determine if the suppressive effect of SYT on the
induction of TARC gene occurs alongside the inhibition
of NF-kB or AP-1. TNF-a/IFN-g (20ngml
 1 each, 18h)
caused a 3.2-fold increase in NF-kB reporter activity
(Fig. 4A), which was inhibited by pretreating the cells
with 300 or 1000mgml
 1 of SYT for 10min (Fig. 4A).
Activation (nuclear translocation) of NF-kB is preceded
by the phosphorylation and subsequent degradation of
the I-kBa subunit (19), and thus, we further examined
phosphorylated I-kBa levels in HaCaT cells. Immunoblot
analysis using specific antibody showed that the phos-
phorylation of I-kBa by TNF-a/IFN-g (20ngml
 1 each,
10min) were also prevented by pretreating with
1000mgml
 1 of SYT for 10min (Fig. 4A).
However, TNF-a/IFN-g did not increase AP-1 reporter
activity in HaCaT cells. Moreover, basal AP-1 reporter
activity was not inhibited by SYT. Instead, there was an
increase in response to SYT 1000mgml
 1 (Fig. 4B). We
also confirmed TNF-a/IFN-g-inducible AP-1 binding
activity by gel shift analysis. Holvoet et al. (20) showed
that TNF-a slightly increased AP-1 DNA binding activity
in HaCaT cells. In their study, basal AP-1 DNA binding
in quiescent cells was detected, as described in the
‘Result’ section. In our experimental condition (serum
deprivation for 12h), the basal AP-1 DNA binding
activity was also strongly found and addition of TNF-a/
IFN-g did not cause further increase in the AP-1 binding
activity. Moreover, SYT did not affect AP-1 DNA
binding activity, which was consistent with results of
AP-1 reporter gene assays (Fig. 4B). It would be possible
that inflammation signal(s)-inducible AP-1 binding was
not found since the basal AP-1 activity was strong in
HaCaT cells.
These results suggest that SYT selectively inhibits
NF-kB activation process, and is associated with its
suppressive effect on TARC induction caused by
inflammatory insults.
Discussion
These results highlighted protective effects of SYT on
development of dermatitis in DNCB-applied Nc/Nga mice.
Figure 2. Effects of SYT on the serum IgE levels in DNCB-applied Nc/Nga mice. DNCB (0.1%) was applied topically to the backs of the Nc/Nga
mice 3 times per week for 10 weeks. SYT (20–60mg per mouse, po) was administered orally 6 times per week during the experiment period. The
serum concentrations of IgE were determined using mouse IgE-specific ELISA kits. The results shown represent the means SD of 5–6 different
samples (significant compared with control, **P50.01; significant compared with the DNCB-applied Nc/Nga group,
#P50.05,
##P50.01).
eCAM 2008;5(2) 177The topical application of DNCB on the backs of
Nc/Nga mice was an efficient tool for inducing severe
and controlled dermatitis within 10 weeks. In contrast,
DNCB itself did not cause any pathological changes in
ICR mice (data not shown), which suggests that the
dermatitis observed in our system mainly results from
the DNCB-inducible potentiation of spontaneous derma-
titis in Nc/Nga mice. Although multiple application
of 2,4,6-trinitro-1-chrolobenzene (TNCB) to mice is a
representative animal model of contact dermatitis (21),
DNCB caused no dermatitis symptoms in our experi-
mental conditions.
Some plant materials contain several chemicals
with anti-allergic and anti-inflammatory activity (22).
There might be anti-allergic or anti-inflammatory materials
such as flavonoids, lignans and catechins in the plant
sources of SYT. However, SYT contain many com-
pounds from eleven medicinal plant sources, and the
structures of components might change into new or
modified compounds during the boiling step. Therefore,
it is impossible to isolate all the active constituents from
SYT. Nc/Nga mice topically applied with DNCB were
used to determine the anti-dermatitic effect of SYT
in vivo. The oral administration of SYT effectively
prevented development of dermatitis, as evidenced by
histology examination. Moreover, ELISA assay results
confirmed that a SYT treatment inhibited increase in
serum IgE level. SYT is often prescribed to patients with
Figure 3. Effects of SYT on the TNF-a/IFN-g-induced production of TARC. The HaCaT cells were incubated in a medium containing SYT for
10min and treated with TNF-a/IFN-g (20ngml
 1, each) for 24h (protein) or 3h (mRNA). (A) Effect of SYT on the TNF-a/IFN-g-induced
production of TARC in HaCaT cells. The concentration of TARC in the medium was determined using TARC-specific ELISA assays. The upper
insert in the figure shows that TARC production is maximally enhanced in the TNF-a/IFN-g-co-treated group. The results shown represent the
mean SD of four different samples (significant compared with control, *P50.05, **P50.01; significant compared with TNF-a/IFN-g-treated
group,
#P50.05,
##P50.01). (B) The TARC mRNA expression levels were determined by RT-PCR analysis. The mRNA expression of the S16 r was
comparable among the samples. These results were confirmed by repeated experiments.
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and these results provide the necessary scientific evidence
of its clinical efficacy.
TARC functions as a selective chemoattractant and
assists in recruitment and migration of Th2 cells, which
express CCR4 (12). TARC antibody therapy reduces the
development of allergic airway inflammation and hyper-
responsiveness (23). Therefore, TARC may be an impor-
tant mediator that exaggerates atopic dermatitis. The
clinical and pharmacological efficacy of SYT on the
inhibition of dermatitis might be associated with its
inhibitory actions on TARC production in keratinocytes
Figure 4. Effects of SYT on the NF-kB and AP-1 activities. (A) NF-kB reporter gene analysis and I-kBa phosphorylation. The induction of luciferase
activity by TNF-a/IFN-g in HaCaT cells transiently transfected with the pNF-kB-Luc construct, which contained the 3-times repeated NF-kB
binding sequences, was confirmed using a luminometer. A dual luciferase reporter gene assay was performed on the lysed cells that had been
co-transfected with the pNF-kB-Luc (firefly luciferase) and pRL-SV (Renilla luciferase)(a ratio of 200:1) after exposing them to TNF-a/IFN-g
(20ngml
 1, each) and SYT (300 or 1000mgml
 1) for 18h. The activation of the reporter gene was calculated as the relative change in the Renilla
luciferase activity. The data represents the mean SD of four separate experiments (significant compared with control, **P50.01; significant
compared with the TNF-a/IFN-g-treated group,
##P50.01). The levels of phosphorylated I-kBa were determined using specific antibody. Cell lysates
were obtained 5min after exposure of HaCaT cells to TNF-a/IFN-g (20ngml
 1, each). (B) AP-1 reporter gene analysis and gel shift assay. The cells
were transfected with the pAP-1-Luc plasmid, and reporter gene analysis was performed as reported in panel (A). The data is represented as a mean
  SD of four separate experiments (significant compared with the control, *P50.05). Gel shift assays were performed with nuclear extracts prepared
from HaCaT cells cultured with or without TNF-a/IFN-g (20ngml
 1, each) for 1h. All lanes were loaded with 10 mg of nuclear extracts and labeled
AP-1 DNA consensus sequence.
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expression are potently blocked in HaCaT cells exposed
to SYT. The promoter of the human TARC gene contains
several homologous consensus sequences for the binding of
transcription factors including STAT, NF-kB and AP-1
(15). Among these transcription factors, either NF-kBo r
AP-1 is important for transcription of the human TARC
gene (16,18). In this study, SYT selectively suppressed the
increased reporter activity of the NF-kB promoter in the
lysates obtained from HaCaT cells treated with TNF-a/
IFN-g. Therefore, the inhibition of NF-kB by SYT may
block induction of TARC in TNF-a/IFN-g-treated kera-
tinocytes. Because herbal medicine extracts are extremely
metabolized in liver and the pharmacological activity of
metabolites is distinct from that of parent herbal medicine,
treatment of HaCaT cells with SYT may not reflect in vivo
effects of SYT. However, considering relatively high doses
of SYT for treatment of dermatitis in animal models or in
clinical situations, hepatic metabolism of SYT could be
saturated and unchanged constituents of SYT may affect
NF-kB activities in keratinocytes.
In conclusion, chronic administration of SYT, at doses of
20–60mg per mice per day ameliorates development of
dermatitis in Nc/Nga mice. These beneficial effects may at
least in part be associated with the inhibitory effect of SYT
on TARC production from keratinocyte in dermatitic
lesions. The NF-kB inhibitory action might be a possible
mechanism for anti-TARC production and anti-dermatitis
effects of SYT.
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